CR7797A - Preparacion solida - Google Patents

Preparacion solida

Info

Publication number
CR7797A
CR7797A CR7797A CR7797A CR7797A CR 7797 A CR7797 A CR 7797A CR 7797 A CR7797 A CR 7797A CR 7797 A CR7797 A CR 7797A CR 7797 A CR7797 A CR 7797A
Authority
CR
Costa Rica
Prior art keywords
solid preparation
preparation
active ingredient
insulin
except
Prior art date
Application number
CR7797A
Other languages
English (en)
Spanish (es)
Inventor
Koike Masahiko
Koyama Hiroyoshi
Hamaguchi Naoru
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32064024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR7797(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR7797A publication Critical patent/CR7797A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CR7797A 2002-10-07 2005-04-19 Preparacion solida CR7797A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002294045 2002-10-07

Publications (1)

Publication Number Publication Date
CR7797A true CR7797A (es) 2005-11-15

Family

ID=32064024

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7797A CR7797A (es) 2002-10-07 2005-04-19 Preparacion solida

Country Status (25)

Country Link
US (1) US9101660B2 (enExample)
EP (1) EP1561472B2 (enExample)
JP (2) JP4236553B2 (enExample)
KR (2) KR20070119095A (enExample)
CN (1) CN100427143C (enExample)
AU (1) AU2003271103B2 (enExample)
BR (1) BR0315082A (enExample)
CA (1) CA2501587C (enExample)
CO (1) CO5700740A2 (enExample)
CR (1) CR7797A (enExample)
CY (1) CY1114863T1 (enExample)
DK (1) DK1561472T3 (enExample)
ES (1) ES2437072T5 (enExample)
IL (1) IL167835A (enExample)
MA (1) MA27487A1 (enExample)
MX (1) MXPA05003668A (enExample)
NO (1) NO332993B1 (enExample)
NZ (2) NZ539711A (enExample)
PL (1) PL219608B1 (enExample)
PT (1) PT1561472E (enExample)
RU (1) RU2357757C2 (enExample)
SI (1) SI1561472T1 (enExample)
UA (1) UA80991C2 (enExample)
WO (1) WO2004030700A1 (enExample)
ZA (1) ZA200503507B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407074A (pt) 2003-01-29 2006-01-24 Takeda Pharmaceutical Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
PL1677792T3 (pl) 2003-10-31 2016-05-31 Takeda Pharmaceuticals Co Stały preparat zawierający pioglitazon, glimepiryd i ester polioksyetylenosorbitanu z kwasem tłuszczowym
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
PL1878426T3 (pl) * 2005-04-26 2010-11-30 Sumitomo Dainippon Pharma Co Ltd Preparat w formie granulatu zawierający związek biguanidu
HRP20160679T1 (hr) 2005-12-22 2016-07-15 Takeda Pharmaceutical Company Limited Kruti pripravak koji sadrži senzibilizator inzulina
KR101220643B1 (ko) * 2006-08-16 2013-01-14 알리코제약(주) 사포그릴레이트 함유 경구투여 형태의 약제
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
JP4832271B2 (ja) * 2006-12-11 2011-12-07 花王株式会社 粉末圧縮錠剤
AR067557A1 (es) * 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
US8563500B2 (en) 2007-09-05 2013-10-22 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
CN101417130B (zh) * 2007-10-22 2010-10-06 鲁南制药集团股份有限公司 一种治疗ⅱ型糖尿病及其并发症的药物组合物
TR200803177A2 (tr) * 2008-05-06 2009-11-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
WO2010084504A2 (en) * 2008-05-26 2010-07-29 Sun Pharmaceutical Industries Ltd. A stable, oral solid dosage form
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
ES2550033T3 (es) 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
US20130217778A1 (en) * 2010-07-21 2013-08-22 Herman H. Vandenburgh Methods and compositions for the improvement of skeletal muscle function in a mammal
EP2441442A1 (en) 2010-10-08 2012-04-18 LEK Pharmaceuticals d.d. A pharmaceutical composition comprising a thiazolidinedione
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
RU2465896C2 (ru) * 2011-01-20 2012-11-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая противодиабетическая композиция пролонгированного действия
CN105125539A (zh) * 2015-08-05 2015-12-09 浙江华海药业股份有限公司 吡格列酮二甲双胍片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331839T2 (de) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1380308B1 (en) 1996-07-12 2008-07-09 Daiichi Pharmaceutical Co., Ltd. Quickly disintegrable compression-molded materials and process for producing the same
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020004515A1 (en) 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
AP1279A (en) * 1997-06-18 2004-05-20 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin.
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
JPH1160476A (ja) 1997-08-25 1999-03-02 Taisho Pharmaceut Co Ltd 圧縮固形組成物
CA2320900C (en) 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
ATE481090T1 (de) * 1998-07-28 2010-10-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
US6117451A (en) * 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
WO2000028989A1 (en) 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
WO2000038666A2 (en) 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
CA2371391A1 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
WO2001035940A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
US6403121B1 (en) 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
JP2001335469A (ja) * 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
FR2812547B1 (fr) 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2002087965A (ja) * 2000-09-14 2002-03-27 Lion Corp 口中崩壊性アスピリン含有錠剤
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
CA2492722A1 (en) 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited Production method of coated preparations

Also Published As

Publication number Publication date
US20050287207A1 (en) 2005-12-29
PT1561472E (pt) 2013-12-09
CO5700740A2 (es) 2006-11-30
NO20052239L (no) 2005-06-29
RU2005113999A (ru) 2005-12-10
KR20070119095A (ko) 2007-12-18
DK1561472T3 (da) 2013-11-11
NZ552559A (en) 2008-04-30
US9101660B2 (en) 2015-08-11
ES2437072T3 (es) 2014-01-08
JP2004149521A (ja) 2004-05-27
NZ539711A (en) 2007-09-28
SI1561472T1 (sl) 2014-01-31
PL219608B1 (pl) 2015-06-30
PL376176A1 (en) 2005-12-27
KR100820609B1 (ko) 2008-04-10
BR0315082A (pt) 2005-08-16
ZA200503507B (en) 2006-08-30
HK1080385A1 (en) 2006-04-28
AU2003271103B2 (en) 2008-02-28
RU2357757C2 (ru) 2009-06-10
EP1561472B2 (en) 2021-01-20
EP1561472A1 (en) 2005-08-10
MXPA05003668A (es) 2005-06-08
CY1114863T1 (el) 2016-12-14
JP4236553B2 (ja) 2009-03-11
WO2004030700A1 (ja) 2004-04-15
NO332993B1 (no) 2013-02-11
CA2501587C (en) 2008-06-03
CA2501587A1 (en) 2004-04-15
EP1561472B1 (en) 2013-10-02
ES2437072T5 (es) 2021-10-13
UA80991C2 (en) 2007-11-26
MA27487A1 (fr) 2005-08-01
JP2008208141A (ja) 2008-09-11
AU2003271103A1 (en) 2004-04-23
KR20050070039A (ko) 2005-07-05
CN100427143C (zh) 2008-10-22
EP1561472A4 (en) 2009-07-08
IL167835A (en) 2010-11-30
NO20052239D0 (no) 2005-05-06
CN1717253A (zh) 2006-01-04

Similar Documents

Publication Publication Date Title
CR7797A (es) Preparacion solida
CR10992A (es) Preparacion solida que comprende alogliptina y pioglitazona
ECSP077368A (es) Mecanismo de visualización de dosis para un dispositivo para la administración de fármacos
NO20073033L (no) Cytotoksiske midler innbefattende nye taksaner
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
ECSP12012056A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
ES2376043T3 (es) Derivados de indazol para el tratamiento de enfermedades inducidas por hsp90.
BRPI0606397A (pt) derivados de 1-tio-d-glucitol
MY159203A (en) Solid preparation comprising alogliptin and metformin hydrochloride
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
CY1113755T1 (el) Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
MX2009011900A (es) Curacion de herida diabetica.
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
AR062925A1 (es) Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
TW200722420A (en) Propane-1,3-dion derivative or salt thereof
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
PE20051156A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
PE20210367A1 (es) Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
AR132113A1 (es) Forma sólida de derivados de pirrolidona como activador de glucoquinasa
MX2025007988A (es) Composicion inyectable de accion prolongada (lai) de cariprazina